Determination	O
of	O
eprosartan	O
in	O
human	O
plasma	B-Organism_substance
and	O
urine	B-Organism_substance
by	O
LC	O
/	O
MS	O
/	O
MS	O
.	O

A	O
protein	O
precipitation	O
,	O
liquid	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
/	O
MS	O
/	O
MS	O
)	O
method	O
has	O
been	O
developed	O
and	O
validated	O
for	O
the	O
determination	O
of	O
eprosartan	O
in	O
human	O
plasma	B-Organism_substance
and	O
urine	B-Organism_substance
.	O

The	O
solvent	O
system	O
also	O
served	O
as	O
a	O
protein	O
precipitation	O
reagent	O
.	O

The	O
chromatographic	O
separation	O
was	O
achieved	O
on	O
a	O
CAPCELL	O
PAK	O
C18	O
column	O
(	O
50	O
mmx2	O
.	O
0	O
mm	O
,	O
5	O
microm	O
,	O
Shiseido	O
)	O
.	O

A	O
mobile	O
phase	O
was	O
consisted	O
of	O
0	O
.	O
5	O
%	O
formic	O
acid	O
in	O
water	O
and	O
0	O
.	O
5	O
%	O
formic	O
acid	O
in	O
acetonitrile	O
(	O
72	O
:	O
28	O
)	O
.	O

Detection	O
was	O
by	O
positive	O
ion	O
electrospray	O
tandem	O
mass	O
spectrometry	O
on	O
a	O
Sciex	O
API3000	O
.	O

The	O
standard	O
curves	O
,	O
which	O
ranged	O
from	O
5	O
to	O
2000	O
ng	O
/	O
mL	O
in	O
human	O
plasma	B-Organism_substance
and	O
from	O
0	O
.	O
25	O
to	O
50	O
microg	O
/	O
mL	O
in	O
urine	B-Organism_substance
,	O
were	O
fitted	O
to	O
a	O
1	O
/	O
x	O
weighted	O
quadratic	O
regression	O
model	O
.	O

The	O
method	O
proved	O
to	O
be	O
accurate	O
,	O
specific	O
and	O
sensitive	O
enough	O
to	O
be	O
successfully	O
applied	O
to	O
a	O
pharmacokinetic	O
study	O
.	O

